Cadence Pharmaceuticals Company Profile (NASDAQ:CADX)

About Cadence Pharmaceuticals (NASDAQ:CADX)

Cadence Pharmaceuticals logoCadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CADX
  • CUSIP: 12738T10
  • Web: N/A
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: 26.38
  • P/E Growth:
  • Dividend Yield: 1.0%

Frequently Asked Questions for Cadence Pharmaceuticals (NASDAQ:CADX)

What is Cadence Pharmaceuticals' stock symbol?

Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."

Who are some of Cadence Pharmaceuticals' key competitors?

How do I buy Cadence Pharmaceuticals stock?

Shares of Cadence Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cadence Pharmaceuticals' stock price today?

One share of Cadence Pharmaceuticals stock can currently be purchased for approximately $13.98.

MarketBeat Community Rating for Cadence Pharmaceuticals (NASDAQ CADX)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cadence Pharmaceuticals (NASDAQ:CADX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cadence Pharmaceuticals (NASDAQ:CADX)
No equities research coverage for this company has been tracked by


Earnings History for Cadence Pharmaceuticals (NASDAQ:CADX)
Earnings by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)
Earnings History by Quarter for Cadence Pharmaceuticals (NASDAQ CADX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2014Q413($0.04)($0.05)$32.51 million$33.30 millionViewN/AView Earnings Details
11/5/2012Q312($0.19)($0.19)$14.16 million$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cadence Pharmaceuticals (NASDAQ:CADX)
Current Year EPS Consensus Estimate: $0.14 EPS
Next Year EPS Consensus Estimate: $0.53 EPS


Dividend History for Cadence Pharmaceuticals (NASDAQ:CADX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cadence Pharmaceuticals (NASDAQ:CADX)
Insider Trades by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)
Insider Trades by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2013William LarueCFOSell8,500$9.12$77,520.00View SEC Filing  
12/2/2013Scott ByrdSVPSell7,812$9.16$71,557.92View SEC Filing  
11/18/2013William LarueCFOSell36,000$7.30$262,800.00View SEC Filing  
7/22/2013Hazel M AkerSVPSell6,507$7.81$50,819.67View SEC Filing  
7/17/2013William R LarueCFOSell9,000$7.26$65,340.00View SEC Filing  
7/15/2013Hazel M AkerSVPSell6,508$7.34$47,768.72View SEC Filing  
6/27/2013William R LarueCFOSell9,000$7.20$64,800.00View SEC Filing  
6/10/2013Malcolm Lloyd-SmithSVPSell4,000$7.44$29,760.00View SEC Filing  
6/7/2013Scott A ByrdSVPSell67,115$7.53$505,375.95View SEC Filing  
3/12/2013Parters Vii L P DomainMajor ShareholderSell10,464$5.36$56,087.04View SEC Filing  
2/14/2013Parters Vii L P DomainMajor ShareholderSell8,714$5.00$43,570.00View SEC Filing  
2/1/2013Parters Vii L P DomainMajor ShareholderSell9,769$4.85$47,379.65View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cadence Pharmaceuticals (NASDAQ:CADX)
Latest Headlines for Cadence Pharmaceuticals (NASDAQ:CADX)



Cadence Pharmaceuticals (CADX) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff